This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Enrollment
4
Revlite Q switched Nd:YAG 1064nm
Trivantage Q switched Nd: YAG 1064nm
NY Laser and Skin Care
New York, New York, United States
Changes in Melasma Determined by Physician
The Global Aesthetic Improvement scale was used to determine the amount of improvement. This scale ranges from 1 to 5, where 1 is very much improved, 2 is much improved, 3 is improved, 4 is no change, and 5 is worsened.
Time frame: 3 months post last treatment
Universal Pain Scale for Subject Tolerability
The subject pain tolerability was assessed using the Universal Pain Scale. This scale ranges from 0 (no pain) to 10 (worst pain possible).
Time frame: 3 months post last treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.